PlainRecalls
FDA Drug Critical Class I Terminated

Amikacin Sulfate injection USP,1 gm/4 mL (250 mg/mL) 4mL vial, Rx only, Manufactured in Hungary For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454. Individual Pack NDC 0703-9040-01, Shelf Pack NDC 0703-9040-03

Reported: June 1, 2016 Initiated: March 9, 2016 #D-0859-2016

Product Description

Amikacin Sulfate injection USP,1 gm/4 mL (250 mg/mL) 4mL vial, Rx only, Manufactured in Hungary For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454. Individual Pack NDC 0703-9040-01, Shelf Pack NDC 0703-9040-03

Reason for Recall

Presence of Particulate Matter: particulate matter identified as glass in one vial.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
6,291 units
Distribution
Nationwide and Puerto Rico
Location
North Wales, PA

Frequently Asked Questions

What product was recalled?
Amikacin Sulfate injection USP,1 gm/4 mL (250 mg/mL) 4mL vial, Rx only, Manufactured in Hungary For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454. Individual Pack NDC 0703-9040-01, Shelf Pack NDC 0703-9040-03. Recalled by Teva Pharmaceuticals USA. Units affected: 6,291 units.
Why was this product recalled?
Presence of Particulate Matter: particulate matter identified as glass in one vial.
Which agency issued this recall?
This recall was issued by the FDA Drug on June 1, 2016. Severity: Critical. Recall number: D-0859-2016.